Reuters logo
BRIEF-Idera Pharmaceuticals and Vivelix Pharmaceuticals, Ltd enter into license agreement
2016年11月28日 / 中午12点22分 / 1 年前

BRIEF-Idera Pharmaceuticals and Vivelix Pharmaceuticals, Ltd enter into license agreement

Nov 28 (Reuters) - Idera Pharmaceuticals Inc :

* Press release - Idera Pharmaceuticals and Vivelix Pharmaceuticals, Ltd. Enter into exclusive license agreement for the worldwide rights to IMO-9200

* Idera Pharmaceuticals Inc - under terms of agreement, idera will receive an upfront fee of $15 million

* Idera Pharmaceuticals Inc - will be eligible for future imo-9200 related development, regulatory and sales milestone payments totaling up to $140 million

* Idera Pharmaceuticals Inc - will be eligible for escalating royalties ranging from mid single-digits to low double-digits of global net sales

* Idera Pharmaceuticals Inc -under terms, idera is responsible for developing potential back-up compounds to imo-9200

* Idera Pharmaceuticals - idera will be eligible for related development, regulatory sales and milestone payments totaling up to $52.5 million

* Idera Pharmaceuticals Inc - as part of agreement, idera has agreed to create and characterize potential back-up compounds for vivelix Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below